Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin in R/R Angioimmunoblastic T-cell Lymphoma
NCT03070964Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 4
01
Overview
A Phase 2 trial of plitidepsin in angioimmunoblastic T-cell lymphoma (AITL), sponsored by PharmaMar. Started Oct 2016; status: terminated.
02
Drugs
plitidepsin
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT03070964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070964.